Reviewer's report
Title:Pharmacologic cholinesterase inhibition improves survival in
acetaminophen-induced acute liver failure in the mouse
Version:1Date:19 February 2014
Reviewer: Ali Canbay
Reviewer's report:
The manuscript of Steinebrunner et al. handles an important therapeutical
approach of Acetaminophen (APAP) caused acute liver failure (ALF).
In a mouse model of APAP-induced ALF the authors investigated the
co-treatment with the cholinesterase inhibitor neostigmine as a potential
therapeutic agent in APAP-mediated ALF. BALB/c mice were treated with
neostigmine prior and after APAP-injection. Co-treatment with neostigmine could
improve overall survival rates as well as hepatocellular damage, cell death and
the release of pro-inflammatory mediators such as IL-1# and TNF-#. The study
could show that the cholinesterase inhibitor neostigmine may have a beneficial
effect within the therapy of ALF in a mouse model.
The results are reported in a clear and well-organized manner with established
and adequate methods and exactness.
While the results shown depict an improving role of neostigmine in ALF-therapy it
would be interesting how this cholinesterase inhibitor could probably support the
common therapy with NAC. The authors should include this issue to their
discussion. Furthermore the authors should include a section within the
discussion that focuses more detailed on the role of cell death (apoptosis and
overall cell death) in APAP-induced ALF with an indication of the publication of
Bechmann et. al. (J Hepatol. 2010 Oct;53(4):639-47.) that describe the
supporting role of cell death markers within ALF-therapy and as useful prediction
markers.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
I declare that I have no competing interests
Reviewer's report
Title:Pharmacologic cholinesterase inhibition improves survival in
acetaminophen-induced acute liver failure in the mouse
Version:1Date:19 February 2014
Reviewer: Ali Canbay
Reviewer's report:
The manuscript of Steinebrunner et al. handles an important therapeutical
approach of Acetaminophen (APAP) caused acute liver failure (ALF).
In a mouse model of APAP-induced ALF the authors investigated the
co-treatment with the cholinesterase inhibitor neostigmine as a potential
therapeutic agent in APAP-mediated ALF. BALB/c mice were treated with
neostigmine prior and after APAP-injection. Co-treatment with neostigmine could
improve overall survival rates as well as hepatocellular damage, cell death and
the release of pro-inflammatory mediators such as IL-1# and TNF-#. The study
could show that the cholinesterase inhibitor neostigmine may have a beneficial
effect within the therapy of ALF in a mouse model.
The results are reported in a clear and well-organized manner with established
and adequate methods and exactness.
While the results shown depict an improving role of neostigmine in ALF-therapy it
would be interesting how this cholinesterase inhibitor could probably support the
common therapy with NAC. The authors should include this issue to their
discussion. Furthermore the authors should include a section within the
discussion that focuses more detailed on the role of cell death (apoptosis and
overall cell death) in APAP-induced ALF with an indication of the publication of
Bechmann et. al. (J Hepatol. 2010 Oct;53(4):639-47.) that describe the
supporting role of cell death markers within ALF-therapy and as useful prediction
markers.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
I declare that I have no competing interests
Please review this paper.
user
Reviewer's report
Title:Pharmacologic cholinesterase inhibition improves survival in
acetaminophen-induced acute liver failure in the mouse
Version:1Date:19 February 2014
Reviewer: Ali Canbay
Reviewer's report:
The manuscript of Steinebrunner et al. handles an important therapeutical
approach of Acetaminophen (APAP) caused acute liver failure (ALF).
In a mouse model of APAP-induced ALF the authors investigated the
co-treatment with the cholinesterase inhibitor neostigmine as a potential
therapeutic agent in APAP-mediated ALF. BALB/c mice were treated with
neostigmine prior and after APAP-injection. Co-treatment with neostigmine could
improve overall survival rates as well as hepatocellular damage, cell death and
the release of pro-inflammatory mediators such as IL-1# and TNF-#. The study
could show that the cholinesterase inhibitor neostigmine may have a beneficial
effect within the therapy of ALF in a mouse model.
The results are reported in a clear and well-organized manner with established
and adequate methods and exactness.
While the results shown depict an improving role of neostigmine in ALF-therapy it
would be interesting how this cholinesterase inhibitor could probably support the
common therapy with NAC. The authors should include this issue to their
discussion. Furthermore the authors should include a section within the
discussion that focuses more detailed on the role of cell death (apoptosis and
overall cell death) in APAP-induced ALF with an indication of the publication of
Bechmann et. al. (J Hepatol. 2010 Oct;53(4):639-47.) that describe the
supporting role of cell death markers within ALF-therapy and as useful prediction
markers.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
I declare that I have no competing interests
assistant